AI software as a medical device for second opinion and therapy planning in retinal diseases
deepeye Medical GmbH
MunichNew on Amplifa
About deepeye Medical
deepeye Medical GmbH develops AI-based software as a medical device for ophthalmology. The core product deepeye TPS supports ophthalmologists with a second opinion (second reading) on any OCT scan and with planning of anti-VEGF therapies for neovascular age-related macular degeneration (nAMD); further functions include biomarker visualization, prediction of treatment need over 12 months, and integration with OCT devices and imaging software such as HEYEX2. The foundation is the analysis of large retinal therapy datasets, including data from the teleophthalmological network in Münster. For pharmaceutical companies, medical device manufacturers, and payers, the company offers a flexible AI platform for data analysis in clinical phase III/IV trials. deepeye was founded in Munich in 2021 and works with partners such as Novartis, Bayer, and the University Eye Hospital Munich (LMU).
- Site
- München
- Processes
- AI report/second opinion for OCT, Anti-VEGF therapy planning (deepeye TPS), Biomarker visualization, Prediction of treatment need (12 months), Integration with OCT devices and imaging software (e.g., HEYEX2), Data analysis for clinical phase III/IV trials
- Materials
- Software as a Medical Device (SaMD), AI/Machine Learning Models
- Certificates
- CE marking (Class IIa) deepeye TPS, CE marking Class IIa (EU MDR)
- Founded
- 2021
- Industries
- Ophthalmology, Medical technology/Software as a Medical Device, Pharma (anti-VEGF therapy), Healthcare/eye clinics
- 01
Data acquisition from OCT and therapy courses
- 02
AI analysis of therapy data
- 03
Second opinion/report with biomarker visualization
- 04
Therapy need prediction (12 months)
- 05
Integration with OCT devices and imaging software
Services & Processes
Software as a Medical Device (SaMD)
deepeye TPS is CE-marked software for supporting anti-VEGF therapy planning in nAMD.
AI/Machine Learning Models
Predictive models for second opinion, disease activity, and treatment need based on retinal therapy datasets.
Locations
Munich
DEHeadquarters
Products & Functions
Inside the production
Industries
Additional services
Reference customers
Quality & Regulatory
deepeye TPS is CE-marked as a Class IIa medical device under EU MDR 2017/745; certification was carried out by the Notified Body Kiwa Assurance.
| Evidence | Munich |
|---|---|
| CE marking Class IIa (EU MDR) |
History
- 2011
Medical co-founders establish one of the first teleophthalmological networks worldwide (the Münster "Portal") for second opinions on retinal therapy
- 2014
Digital study protocol (eCRF) for outcome evaluation
- 2016
One of the first publications on improving therapy adherence and persistence
- 2018
Start of AI analysis of therapy data with Prof. Reiner Kurzhals
- 2019
First results from the Münster Portal: better outcomes and more patients under therapy than standard care
- 2020
DOC presentation: 3x better outcomes, 2x therapy persistence; German AI Prize for the deepeye research project
- 2021
Founding of deepeye Medical GmbH
- 2022
First publication on AI second opinion, supported by Novartis; collaboration with the University Eye Hospital Munich (LMU)
- 2023
Publication with Bayer: transfer of the prognostic AI to different populations, devices, and therapies
- 2025
deepeye TPS receives CE marking Class IIa under EU MDR (Notified Body Kiwa Assurance)